1727. Sustained Antimicrobial Activity of a Novel Disinfectant Against Healthcare Pathogens
Session: Oral Abstract Session: The World Around Us: Reducing Exposures to Pathogens in the Healthcare Environment
Saturday, October 6, 2018: 9:15 AM
Room: S 156

Background: Environmental contamination plays an important role in the transmission of MRSA, VRE and C. difficile. Suboptimal compliance with hand hygiene or inappropriate glove use can result in indirect transfer of these pathogens to patients. This study evaluates a novel disinfectant that claims to kill microbes on surfaces for ≥24 hours.

Methods: We investigated the persistent antimicrobial activity of a novel disinfectant using an EPA protocol for sustained disinfecting activity. In brief, surfaces are inoculated, treated with the novel disinfectant, allowed to dry, and then abraded using a standardized abrasion machine under multiple alternating wet and dry wipe conditions (N=12) interspersed with 6 re-inoculations. After 24 hours, the surface was re-inoculated a final time and ability of the disinfectant to kill ≥99.9% of 9 test microbes within 5min was measured on 3 test surfaces (glass, formica, and stainless steel).

Results: The novel disinfectant demonstrated a 3-5 log10 reduction in 5min when testing S. aureus, VRE, C. auris, CRE E. coli and antibiotic-sensitive strains of E. coli, and Enterobacter sp. (Table). The disinfectant demonstrated lower killing for CRE isolates of Enterobacter sp and K. pneumoniae, and for antibiotic-sensitive K. pneumoniae (~2 log10 reduction in 5min). When the novel disinfectant was compared to three other commonly used disinfectants using the same methodology with S. aureus, the mean log10 reductions were: 4.4 (novel disinfectant); 0.9 (quat-alcohol); 0.2 (improved hydrogen peroxide); and 0.1 (chlorine).

Conclusion: Persistent disinfectants may reduce or eliminate the problem of recontamination and minimize the role of environmental surfaces in transmission of healthcare pathogens.

Table. Log10 Reduction of a Novel Disinfectant with Persistent Antimicrobial Activity

Test Pathogen

Mean Log10 Reduction, 95% CI n=4

A

S. aureus*

4.4 (3.9, 5.0)

B

S. aureus (formica)

4.1 (3.8, 4.4)

C

S. aureus (stainless steel)

5.5 (5.2, 5.9)

D

Vancomycin-resistant Enterococcus

≥4.5

E

E. coli

4.8 (4.6, 5.0)

F

Enterobacter sp.

4.1 (3.5, 4.6)

G

Candida auris

≥5.0

H

K. pneumoniae

1.5 (1.4, 1.6)

I

CRE E. coli

3.0 (2.6, 3.4)

J

CRE Enterobacter

2.0 (1.6, 2.4)

K

CRE K. pneumoniae

2.1 (1.8, 2.4)

*Test surface is glass unless otherwise specified

William Rutala, BS, MS, PhD, MPH1, Maria Gergen, MT (ASCP)2, Emily Sickbert-Bennett, PhD, MS2,3, Deverick J. Anderson, MD, MPH, FIDSA, FSHEA4 and David Weber, MD, MPH5, (1)Medicine, University of North Carolina, Chapel Hill, NC, (2)Hospital Epidemiology, University of North Carolina Health Care, Chapel Hill, NC, (3)UNC Hospitals, Chapel Hill, NC, (4)Duke Center for Antimicrobial Stewardship and Infection Prevention, Durham, NC, (5)Medicine and Pediatrics, University of North Carolina School of Medicine, Chapel Hill, NC

Disclosures:

W. Rutala, PDI: Consultant and Speaker's Bureau , Consulting fee and Speaker honorarium .

M. Gergen, None

E. Sickbert-Bennett, None

D. J. Anderson, None

D. Weber, PDI: Consultant , Consulting fee .

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.